Health Trials

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

ConditionGeographic Atrophy Secondary to Age-related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age55+
SponsorComplement Therapeutics

About this trial

This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).

Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • CTx001

Treatment groups

75 Participants
are divided into 5 treatment groups

Locations

5
United Kingdom
The Retina Clinic LondonW1G 7LB, LondonLondon, United Kingdom
United States
Midwest Eye Institute46290, CarmelIndiana, United States
Sierra Eye Associates89502, RenoNevada, United States
Retina Foundation of the Southwest75231, DallasTexas, United States

Sponsors and collaborators

Complement Therapeutics

Lead sponsor

Source ClinicalTrials.gov